Effect of PCSK9 inhibitor combined with statin on blood lipid,carotid plaques and inflammatory factors in patients with coronary heart disease
Objective To analyze the effects of PCSK9 inhibitor combined with statin on blood lipids,inflammatory factors and carotid plaque in patients with coronary heart disease.Methods A prospective randomized controlled study was conducted to include 101 patients diagnosed with coronary heart disease combined with hyperlipidemia in the Cardiology Department of Yuxi People's Hospital from September 2022 to December 2022,and they were randomly divided into two groups:observation group(50 cases)was treated with aliciumab plus statins,and control group(51 cases)was treated with statins.Treatment continued for six months.The changes of blood lipids,inflammatory indicators and cervical vascular plaque Crouse scorse of neckl vascular plaques were compared between the two groups after six months of treatment.The incidence of adverse cardiovascular events and adverse reactions were compared between the two groups during the whole follow-up period.Results After 6 months of treatment,the levels of TC,TG,LDL-C,ApoB,Lp(a),hs-CRP,IL-6,PLR,NLR and Crouse scores of carotid plaque in the observation group were all decreased compared with those before treatment,and the decrease rate was significantly higher than those of the control group,the increase rate HDL-C and rate of reaching the standard were all higher than those of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions and cardiovascular adverse events between the two groups(P＞0.05).Conclusions PCSK9 inhibitor combined with statin therapy can rapidly improve blood lipid level,inflammatory and plaque stability in patients with coronary heart disease in the short term,and it is safe in short-term application.
NETL
NSTL
万方数据
